TORONTO, Dec. 21, 2017 (GLOBE NEWSWIRE) — Emblem Corp. (TSX-V:EMC) (EMC.WT) (“Emblem” or the “Company”), has entered into a licensing agreement with Dosecann Inc. (“Dosecann”) pursuant to which Dosecann will begin developing a range of cannabinoid dosage formulations designed to ensure patients are better able to titrate and administer each dose the exact same way.
TORONTO, Dec. 21, 2017 (GLOBE NEWSWIRE) — Emblem Corp. (TSX-V:EMC) (EMC.WT) (“Emblem” or the “Company”), has entered into a licensing agreement with Dosecann Inc. (“Dosecann”) pursuant to which Dosecann will begin developing a range of cannabinoid dosage formulations designed to ensure patients are better able to titrate and administer each dose the exact same way.
The two companies will begin work immediately on the development of a cannabis-oil oral spray dosage form, followed by the development of two separate dose-controlled vaporizers.
The dose can receive royalty payments from Emblem on sales of Emblem-branded products and Emblem with receive royalties from Dosecann on sales of Dosecann-branded products.
“There is substantial evidence that cannabinoids are effective for the treatment of a number of conditions including chronic pain, nausea, and spasticity in patients with Multiple Sclerosis. These advanced dosage forms and the whole strain extracts they contain are designed and formulated to enhance the therapeutic benefits available from medical cannabis.”
Read more at New Cannabis Ventures
